In chronic renal failure patients an increase in heparin dose during haemodialysis is frequently required during the course of therapy with NeoRecormon as a result of the increased packed cell volume.
Hematokriitin nousun seurauksena hepariiniannosta on hemodialyysin aikana usein suurennettava kroonista munuaisten vajaatoimintaa sairastavilla potilailla, jotka saavat NeoRecormon- hoitoa.